|
Name |
Methyl 3-methylpentanoate
|
| Molecular Formula | C7H14O2 | |
| IUPAC Name* |
methyl 3-methylpentanoate
|
|
| SMILES |
CCC(C)CC(=O)OC
|
|
| InChI |
InChI=1S/C7H14O2/c1-4-6(2)5-7(8)9-3/h6H,4-5H2,1-3H3
|
|
| InChIKey |
FHASOOYJUZKVFW-UHFFFAOYSA-N
|
|
| Synonyms |
Methyl 3-methylpentanoate; Methyl 3-methylvalerate; 2177-78-8; METHYL3-METHYLPENTANOATE; Valeric acid, 3-methyl-, methyl ester; Pentanoic acid, 3-methyl-, methyl ester; Pentanoic acid,3-methyl-,methyl ester; methyl-3-methyl pentanoate; Methyl .beta.-methylvalerate; SCHEMBL5711131; DTXSID70334182; 3-Methylvaleric acid methyl ester; 3-Methylvaleric acid, methyl ester; Methyl 3-methylvalerate, >=97.0%; DB-066628; FT-0710427; J-014282; 2,2-[1,4-PHENYLENEBIS(METHYLENE)]BIS-1H-BENZOIMIDAZOLE
|
|
| CAS | 2177-78-8 | |
| PubChem CID | 519891 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 130.18 | ALogp: | 2.4 |
| HBD: | 0 | HBA: | 2 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 26.3 | Aromatic Rings: | 0 |
| Heavy Atoms: | 9 | QED Weighted: | 0.547 |
| Caco-2 Permeability: | -4.292 | MDCK Permeability: | 0.00002950 |
| Pgp-inhibitor: | 0.006 | Pgp-substrate: | 0.004 |
| Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.005 |
| 30% Bioavailability (F30%): | 0.18 |
| Blood-Brain-Barrier Penetration (BBB): | 0.998 | Plasma Protein Binding (PPB): | 31.73% |
| Volume Distribution (VD): | 0.815 | Fu: | 67.60% |
| CYP1A2-inhibitor: | 0.641 | CYP1A2-substrate: | 0.444 |
| CYP2C19-inhibitor: | 0.212 | CYP2C19-substrate: | 0.863 |
| CYP2C9-inhibitor: | 0.112 | CYP2C9-substrate: | 0.38 |
| CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.284 |
| CYP3A4-inhibitor: | 0.022 | CYP3A4-substrate: | 0.268 |
| Clearance (CL): | 10.923 | Half-life (T1/2): | 0.847 |
| hERG Blockers: | 0.009 | Human Hepatotoxicity (H-HT): | 0.13 |
| Drug-inuced Liver Injury (DILI): | 0.202 | AMES Toxicity: | 0.008 |
| Rat Oral Acute Toxicity: | 0.039 | Maximum Recommended Daily Dose: | 0.049 |
| Skin Sensitization: | 0.807 | Carcinogencity: | 0.196 |
| Eye Corrosion: | 0.971 | Eye Irritation: | 0.982 |
| Respiratory Toxicity: | 0.224 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000225 | ![]() |
0.593 | D0ZK8H | ![]() |
0.387 | ||
| ENC000416 | ![]() |
0.484 | D0OL6O | ![]() |
0.289 | ||
| ENC000241 | ![]() |
0.438 | D02KBD | ![]() |
0.255 | ||
| ENC000819 | ![]() |
0.417 | D0G8SQ | ![]() |
0.250 | ||
| ENC000182 | ![]() |
0.407 | D07ZTO | ![]() |
0.250 | ||
| ENC001788 | ![]() |
0.400 | D04MWJ | ![]() |
0.250 | ||
| ENC000235 | ![]() |
0.382 | D00WUF | ![]() |
0.244 | ||
| ENC000382 | ![]() |
0.379 | D0K3LW | ![]() |
0.237 | ||
| ENC001288 | ![]() |
0.378 | D0I5HV | ![]() |
0.233 | ||
| ENC000833 | ![]() |
0.368 | D0U7BW | ![]() |
0.231 | ||